• IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here.

    The OTHER forum is HERE so please stop asking.

[USA] - 8 people (including an 18 year old girl) kena stroke after receiving the Johnson & Johnson coronavirus vaccine

UltimaOnline

Alfrescian (InfP)
Generous Asset
Joined
Jul 16, 2008
Messages
21,969
Points
113
'We Were Flying Blind': A Doctor's Account of a Woman's J&J Vaccine-Related Blood Clot Case

Denise Grady
Sat, 17 April 2021, 10:16 pm


Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, addresses a news conference about the pause in the Johnson & Johnson COVID-19 vaccine, at the White House in Washington on Tuesday, April 13, 2021. (Pete Marovich/The New York Times)

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, addresses a news conference about the pause in the Johnson & Johnson COVID-19 vaccine, at the White House in Washington on Tuesday, April 13, 2021. (Pete Marovich/The New York Times)

An 18-year-old woman was stricken with severe headaches, vomiting, seizures, confusion and weakness in one arm early this month, strokelike symptoms that doctors at a Nevada hospital were shocked to see in someone so young.

Scans found several large blood clots blocking veins that drain blood from the brain, a condition that can disable or kill a patient.

Doctors performed a procedure to suction huge clots from her brain, only to find that new ones had formed.

The patient is one of six women ages 18 to 48 who developed clots in the brain within two weeks of receiving the Johnson & Johnson coronavirus vaccine. One died, and their devastating cases led U.S. health officials to recommend Tuesday that use of the vaccine be paused.

Two more cases have been added since then: one involving a man who was vaccinated during the company’s clinical trials and another involving a woman who received the vaccine after it had been authorized for general use.

As in several of the original cases, the young woman in Nevada was initially treated with heparin, a standard blood-thinner that experts have since learned may actually worsen the rare clotting disorder that has affected small numbers of people who received the Johnson & Johnson or AstraZeneca vaccines in several countries. But until the last few weeks, doctors around the world had little information about the condition, and the doctors in Nevada did not recognize it immediately.

“We were flying blind, based on reports from Europe and the U.K. hematological society,” said Dr. Brian Lipman, an infectious-disease specialist who helped care for the Nevada patient at Dignity Health St. Rose Dominican Hospital, Siena Campus, in Henderson.

The U.S. decision to call for suspension of the use of the vaccine was intended to give officials time to learn more about the rare disorder causing the clots, to assess whether it is linked to the vaccine and to inform doctors and patients about how to recognize symptoms and treat the condition.

https://sg.yahoo.com/news/were-flying-blind-doctors-account-141618443.html
 
US to resume using Johnson and Johnson's COVID-19 vaccine
FILE PHOTO: A vial of the Johnson & Johnson's COVID-19 vaccine is seen at Northwell Health's South Shore University Hospital in Bay Shore, New York, US, Mar 3, 2021. (Photo: Reuters/Shannon Stapleton )
24 Apr 2021 09:05AM
(Updated: 24 Apr 2021 09:06AM)
Bookmark
WASHINGTON: The United States can immediately resume use of Johnson and Johnson's COVID-19 vaccine, top health regulators said on Friday (Apr 23), ending a 10-day pause to investigate the vaccine's link to extremely rare but potentially deadly blood clots.
The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration said in a joint statement that they would warn of the risk of a potentially fatal syndrome involving severe blood clots and low platelets in a fact sheet given to recipients.
Top US FDA officials said the decision was effective immediately, clearing the way for shots in arms as early as Saturday.
"We are no longer recommending a pause in the use of this vaccine," CDC Director Rochelle Walensky told a news briefing. "Based on the in-depth analysis, there is likely an association but the risk is very low."
READ: EU countries ready to start using Johnson & Johnson COVID-19 vaccine as deliveries resume

The agencies made the decision following a meeting by outside advisers to the CDC who recommended that the vaccine pause be ended. The agencies had been investigating the risks of the vaccine.
Earlier on Friday, the CDC panel voted 10 to four that the Johnson and Johnson's vaccine be used as recommended in people 18 years of age and older, the parameters of its current FDA authorisation.
"The committee's recommendation is an essential step toward continuing urgently needed vaccinations in a safe way for millions of people in the US," Johnson and Johnson's Chief Scientific Officer Paul Stoffels said in a statement.
READ: Johnson & Johnson COVID-19 vaccine reviewed for links to additional reports of severe side effects: CDC

The CDC said that there had been 15 total cases of the syndrome, including the six original confirmed cases that all occurred in women. There were three deaths.
While the efficacy of the Johnson and Johnson's vaccine in clinical testing lagged that demonstrated by the other two approved for use in the United States, it has the advantage over the ones produced by Pfizer-BioNTech and Moderna in that it is given with a single dose rather than two.
It also is stored in a refrigerator and does not need to be frozen during transport, which makes it better for hard-to-reach areas.
The US decision follows a similar one by the European Medicines Agency, which on Tuesday said the benefits of Johnson and Johnson's shot outweighed its risks and recommended adding a warning about unusual blood clots with low blood platelet counts to the vaccine's product label. Johnson and Johnson resumed its rollout there.
READ: Johnson & Johnson COVID-19 vaccine manufacturing halted at US plant that had contamination issue

'EXTRAORDINARILY RARE RISK'
"It is an extraordinarily rare risk. A number of vaccines have an extraordinarily rare risk," said Dr Paul Offit of the University of Pennsylvania, a member of the FDA's vaccine advisory panel.
Dr William Moss, executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health, said the vaccine should be used with warnings of the risk as it will help advance the vaccination effort.
"Giving people the choice to receive a single-dose vaccine will help get more people vaccinated faster and will better protect some populations, such as those who are homeless or incarcerated," Moss said by email.
Johnson and Johnson has faced several setbacks since its vaccine gained US emergency authorisation in February, including drawing scrutiny over production shortfalls. FDA inspectors this week cited a long list of serious cleanliness and safety issues at an Emergent BioSolutions plant making the Johnson and Johnson vaccine.
READ: Peeling paint, shoddy cleanups among issues at US plant making Johnson & Johnson's COVID-19 vaccine
Johnson and Johnson shares closed up 0.2 per cent at US$165.52.
The United States has made substantial progress in vaccinating its population in recent months compared to many other countries, with 35 per cent of adults fully vaccinated and 53 per cent having received at least one shot, according to CDC data. The United States has recorded about 570,000 COVID-19 deaths.
 
What happened to the trusted brand we know and love since childhood? :unsure:

HafxJxr.jpg
 
What happened to the trusted brand we know and love since childhood? :unsure:

HafxJxr.jpg



J&J loses bid to overturn baby powder verdict, but damages cut to $2.1 billion
PUBLISHED TUE, JUN 23 202012:48 PM EDT
Reuters

SHAREShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email
KEY POINTS
  • A Missouri appeals court on Tuesday rejected Johnson & Johnson’s bid to throw out a jury verdict in favor of women who blamed their ovarian cancer on its baby powder and other talc products, but reduced its damages award to $2.12 billion from $4.69 billion.
  • The decision by the Missouri Court of Appeals, in a case brought by 22 women, followed J&J’s announcement on May 19 that it would stop selling its talc Johnson’s Baby Powder in the United States and Canada.
  • Johnson & Johnson faces more than 19,000 lawsuits claiming that its talc products caused cancer because of contamination from asbestos.
 
Back
Top